Implications of CRISPR-Cas9 Genome Editing Methods in Atherosclerotic Cardiovascular Diseases

Today, new methods have been developed to treat or modify the natural course of cardiovascular diseases (CVDs), including atherosclerosis, by the clus-tered regularly interspaced short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9) system. Genome-editing tools are CRISPR-related palin-dromic short iteration systems such as CRISPR-Cas9, a valuable technology for achieving somatic and ger-minal genomic manipulation in model cells and organ-isms for various applications, including the creation of deletion alleles. Mutations in genomic deoxyribonu-cleic acid and new genes' placement have emerged. Based on World Health Organization fact sheets, 17.9 million people die from CVDs each year, an esti-mated 32% of all deaths worldwide. 85% of all CVD deaths are due to acute coronary events and strokes. This review discusses the applications of CRISPR-Cas9 technology throughout atherosclerotic disease research and the prospects for future in vivo genome editing therapies. We also describe several limitations that must be considered to achieve the full scientific and therapeutic potential of cardiovascular genome editing in the treatment of atherosclerosis. (Curr Probl Cardiol 2023;48:101603.)